Skip to main content
SpringerLink
Log in

Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment?

  • Practice Point
  • Published:

From Nature Clinical Practice Rheumatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McLaughlin P et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clinc Oncol 16: 2825–2833

    Article  CAS  Google Scholar 

  2. Looney RJ et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus. Arthritis Rheum 50: 2580–2589

    Article  CAS  Google Scholar 

  3. Baert F et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601–608

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Rheumatology Fellow in and MH Weisman is the Director of the Division of Rheumatology, Cedars–Sinai Medical Center, Los Angeles, CA, USA

    Catherine B Driver & Michael H Weisman

Authors
  1. Catherine B Driver
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael H Weisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael H Weisman.

Ethics declarations

Competing interests

Dr Catherine B Driver owns stock in Amgen.

Dr Michael H Weisman is involved in research support for Amgen, Abbott, Bristol Myers Squibb (BMS), Centocor, Genentech, Human Genome Sciences (HGS), PDL. Dr Weisman is also involved as a Consultant and on the Advisory Boar for Abbott, Bristol Myers Squibb (BMS), Coley Pharmaceutical, ELAN, Human Genome Sciences (HGS), Rigel, Roche, Vertex Pharmaceutical, and UCB Pharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Driver, C., Weisman, M. Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment?. Nat Rev Rheumatol 2, 408–409 (2006). https://doi.org/10.1038/ncprheum0255

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0255

  • Springer Nature Limited

Search

Navigation